Literature DB >> 28784612

Early-Stage Metastasis Requires Mdm2 and Not p53 Gain of Function.

Paula M Hauck1, Eric R Wolf2, David J Olivos1,3, Christopher N Batuello2, Kyle C McElyea4, Ciarán P McAtarsney1, R Michael Cournoyer1, George E Sandusky4,5, Lindsey D Mayo6,2,5.   

Abstract

Metastasis of cancer cells to distant organ systems is a complex process that is initiated with the programming of cells in the primary tumor. The formation of distant metastatic foci is correlated with poor prognosis and limited effective treatment options. We and others have correlated Mouse double minute 2 (Mdm2) with metastasis; however, the mechanisms involved have not been elucidated. Here, it is reported that shRNA-mediated silencing of Mdm2 inhibits epithelial-mesenchymal transition (EMT) and cell migration. In vivo analysis demonstrates that silencing Mdm2 in both post-EMT and basal/triple-negative breast cancers resulted in decreased primary tumor vasculature, circulating tumor cells, and metastatic lung foci. Combined, these results demonstrate the importance of Mdm2 in orchestrating the initial stages of migration and metastasis.Implication: Mdm2 is the major factor in the initiation of metastasis. Mol Cancer Res; 15(11); 1598-607. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28784612      PMCID: PMC6688491          DOI: 10.1158/1541-7786.MCR-17-0174

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  7 in total

1.  Mdm2-mediated neddylation of pVHL blocks the induction of antiangiogenic factors.

Authors:  Eric R Wolf; Alexander R Mabry; Blossom Damania; Lindsey D Mayo
Journal:  Oncogene       Date:  2020-06-17       Impact factor: 9.867

2.  Nrf2 protects stellate cells from Smad-dependent cell activation.

Authors:  Vincenzo Prestigiacomo; Laura Suter-Dick
Journal:  PLoS One       Date:  2018-07-20       Impact factor: 3.240

3.  Contemplations on MDMX (MDM4) driving triple negative breast cancer circulating tumor cells and metastasis.

Authors:  Chong Gao; Gu Xiao; Jill Bargonetti
Journal:  Oncotarget       Date:  2019-08-20

4.  Feasibility of Developing Radiotracers for MDM2: Synthesis and Preliminary Evaluation of an 18F-Labeled Analogue of the MDM2 Inhibitor SP-141.

Authors:  Satish K Chitneni; Zhengyuan Zhou; Brian E Watts; Michael R Zalutsky
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-13

5.  MDM2 induces EMT via the B‑Raf signaling pathway through 14‑3‑3.

Authors:  Mengting Ou; Xichao Xu; Ying Chen; Li Li; Lu Zhang; Yi Liao; Weichao Sun; Christine Quach; Jianguo Feng; Liling Tang
Journal:  Oncol Rep       Date:  2021-05-06       Impact factor: 3.906

6.  Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.

Authors:  Chong Gao; Gu Xiao; Alessandra Piersigilli; Jiangtao Gou; Olorunseun Ogunwobi; Jill Bargonetti
Journal:  Breast Cancer Res       Date:  2019-01-14       Impact factor: 6.466

7.  Long Non-Coding RNA CRYBG3 Promotes Lung Cancer Metastasis via Activating the eEF1A1/MDM2/MTBP Axis.

Authors:  Anqing Wu; Jiaxin Tang; Ziyang Guo; Yingchu Dai; Jing Nie; Wentao Hu; Ningang Liu; Caiyong Ye; Shihong Li; Hailong Pei; Guangming Zhou
Journal:  Int J Mol Sci       Date:  2021-03-22       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.